Skip to main content
. 2014 Oct 29;26(1):113–119. doi: 10.1093/annonc/mdu486

Figure 1.

Figure 1.

Outcomes for the subgroup of patients with CNS metastases at baseline. (A) Progression-free survival according to independent review committee, (B) progression-free survival according to investigator assessment, (C) time-to-symptom progression and (D) overall survival. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; T-DM1, trastuzumab emtansine; XL, capecitabine – lapatinib.